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Abstract
Peritoneal fibrosis is one of the most serious complications of peritoneal dialysis, and is characterized
by the activation of peritoneal resident cells (mesothelial cells, endothelial cells, fibroblasts and
macrophages), induction of pro-fibrotic peptides, accumulation and deposition of excess matrix
proteins within the submesothelium, and vasculopathy of the peritoneal microvasculature. In order
to provide novel therapeutic strategies that will allow us to preserve the structural and functional
integrity of the peritoneum during peritoneal dialysis, it is essential to elucidate the mechanisms of
peritoneal fibrosis. There is now compelling evidence to show that elevated glucose concentrations
present in peritoneal dialysis fluids and its by-products play a pivotal role in the initiation of
peritoneal fibrosis. This review will describe the pathogenesis of glucose-mediated peritoneal fibrosis,
and highlight recent in vitro data that may one day be extended to clinical trials, offering effective
treatment in the preservation of the structure of the peritoneum. Such strategies include the
employment of alterative osmotic agents (amino acids or icodextrin), transforming growth factor-β1
antagonists, gene therapy, and pharmacological intervention.
Key words: Fibrosis, glucose, Extracellular matrix, Peritoneal dialysis, peritoneum, Transforming growth
factor-β1
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R E V I E W
A R T I C L E
INTRODUCTION
Peritoneal dialysis (PD) is now well recognized as a
therapy for patients with end-stage renal failure and is
used by 15% of dialysis patients in the developed world.
A major concern of PD that currently remains unresolved
is the progressive deterioration of the peritoneal
membrane leading to fibrosis of varying degrees, and
subsequently loss of peritoneal function. Peritoneal
fibrosis is characterized by the activation of peritoneal
resident cells, induction of growth factors and cytokines,
exfoliation of mesothelial cells, accumulation and
deposition of excess matrix proteins within the
submesothelium, neoangiogenesis and vasculopathy of
the peritoneal microvasculature. Although the biological
mechanisms involved in the initiation and progression
of peritoneal fibrosis remains to be fully elucidated, there
is now compelling evidence to demonstrate that elevated
glucose concentrations in PD solutions play a
predominant role in the detrimental changes observed
within the peritoneum. Until alternative compounds can
fully replace glucose as the osmotic agent in PD
solutions, in order to improve patient survival on PD it
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matrix synthesis and degradation. It can be termed a
pathological wound healing process that exceeds the
physiological repair process in response to chronic
surgical, bacterial, or chemical insult (9) and instigates
the activation of peritoneal resident cells. The onset of
peritoneal fibrosis is associated with the denudation of
the protective mesothelial monolayer, thickening of the
submesothelium, and vasculopathy (10). Previously,
much attention has focused on the changes within the
mesothelium and submesothelium, and it is only recently
that independent researchers have concentrated on the
peritoneal vascular bed since studies have been shown
convincingly that membrane function is not only affected
by peritoneal structural integrity, but also blood vessel
density (11). In this context, morphologic analysis of a
large cohort of peritoneal biopsy specimens obtained
without bias from patients with renal disease
demonstrated an association between ultrafiltration
failure consequent to peritoneal fibrosis, thickening of
the submesothelium, an increase in the number of blood
vessels, and vasculopathy in PD patients that experienced
significant problems during the first 5 years of therapy
(10). Deposition of AGEs have been implicated to
modulate in part, these structural changes (12). Moreover,
this study showed that peritoneal fibrosis was uncommon
in the absence of vasculopathy (10). These observations
were in agreement with previous studies (albeit in a small
number of samples) where Honda et al (13) concluded
that decreased ultrafiltration correlated well with
vasculopathy and interstitial fibrosis. Several researchers
have also documented the thickening and reduplication
of the mesothelial basement membrane, in some cases
exceeding five layers, and have suggested that this is the
result of expansion and altered composition of the
interstitial matrix mediated predominantly by the
induction of collagen type IV synthesis (10,11,13-15).
Peritoneal fibrosis is associated with exaggerated
synthesis of pro-fibrotic peptides such as transforming
growth factor beta-1 (TGF-β1), basic fibroblast growth
factor (bFGF), and vascular endothelial growth factor.
These peptides act in concert to modulate cellular
processes such as cell growth, differentiation, apoptosis,
and extracellular matrix (ECM) synthesis (16-18). Much
attention has focused on the primary role of TGF-β1 in
peritoneal fibrosis since TGF-β1 synthesis is induced by
elevated glucose concentrations, and can initiate fibrosis
by four separate but simultaneous pathways, namely
directly stimulating the synthesis of matrix proteins;
inhibiting the degradation of matrix proteins by
decreasing expression of proteases whilst increasing
synthesis of protease inhibitors; modulating the
expression of integrins on the cells such as to enhance
cell matrix interactions and facilitate matrix deposition,
is essential to design strategies that can alleviate fibrotic
processes that occur within the peritoneum. This review
is going to highlight the mechanism of peritoneal fibrosis
and the potential use of novel strategies in ameliorating
structural changes in the peritoneum.
THE PERITONEUM AND
PERITONEAL DIALYSIS
The peritoneum is the most extensive serous membrane
in the body, and covers the visceral organs and lines the
abdominal cavity. It consists of a monolayer of meso-
thelial cells that rest on a basal lamina underneath which
comprises the interstitium and capillary network.
Although originally thought to be a passive membrane,
the peritoneum is now considered a biologically active
membrane that facilitates the transport and movement of
fluid and particulate matter across the peritoneal cavity
(1). The peritoneal surface area for fluid and solute
exchange is significantly increased by numerous
microvilli situated on the apical side of the mesothelial
cells (1). Peritoneal resident cells (mesothelial cells,
endothelial cells, fibroblasts, and macrophages) are
capable of synthesizing a plethora of cytokines, growth
factors, and matrix proteins that can contribute to the
peritoneal inflammatory response, tissue repair, prevention
of adhesion formation, and in the maintenance of the
structural integrity of the peritoneal membrane (1-5).
The introduction of PD over 2 decades ago has allowed
us to manipulate the peritoneal membrane to act as a
biological dialyzing organ. To maximize the effectiveness
of solute transport and removal of waste, conventional
PD solutions contain bio-incompatible concentrations of
glucose to provide the osmotic drive, lactate to alleviate
metabolic acidosis, and a low pH to prevent the
caramelization of glucose during the heat-sterilization
of PD solutions. This process, however, generates
glucose degradation products (GDPs)–compounds that
are cytotoxic to peritoneal resident cells (6-8), and which
mediate the formation of advanced glycosylated end-
products (AGEs). These factors, either alone or in
combination, are irritants to the peritoneal membrane.
Chronic exposure of the peritoneum to PD solutions,
together with frequent episodes of peritonitis, thus
confers to the peritoneal membrane a chronic
inflammatory response. It is therefore not unexpected
that with increasing duration on PD, structural changes
are observed within the peritoneum, resulting in
peritoneal fibrosis and ultrafiltration failure.
PERITONEAL FIBROSIS
Peritoneal fibrosis is characterized by detrimental
changes in the normal architecture of the peritoneal
membrane due to a disruption of the fine balance between
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an appropriate species whereby their peritoneal
membrane mimics that of the human peritoneal
environment. Given that in some animal models of PD
for example in the rat, the relative peritoneal surface area
is much larger than that of man, and the duration of
therapy is limited, one must evaluate animal data with
some degree of caution.
Clinically, glucose is rapidly transported to the blood
vessels, and has been shown to play a pivotal role in
peritoneal neoangiogenesis leading to diabetiform
alterat ions (30) .  The cl inical  importance of
neoangiogenesis and increased peritoneal vascular
surface area has been underscored by Davies et al (31),
who demonstrated a correlation between the duration of
glucose exposure of the peritoneum and the development
of ultrafiltration failure in PD patients. To prevent
technique failure, it is therefore imperative to replace
glucose as the osmotic agent. In this context, alternative
PD solutions have been formulated that employ non-
glucose osmotic agents such as amino acids or
polyglucose/icodextrin (27). Amino acid-based PD
solutions have been formulated to serve as an additional
phosphate-free nitrogen source that can improve the
nutritional status of PD patients (32). Icodextrin is a high
molecular weight osmotic agent that can induce
ultrafiltration by colloid osmosis. Because of its low
absorption rate, icodextrin-based PD fluid is efficient in
inducing ultrafiltration during long dwells, and is thus
particularly beneficial to PD patients with ultrafiltration
failure (33). Although both fluids have been shown to
reduce metabolic and local glucose induced stress, it is
unfortunate that neither amino acid-based nor icodextrin-
based PD solutions can fully replace glucose-based PD
fluids due to nitrogenous waste production, and the
accumulation of maltose in the circulation respectively
(27). However, preliminary studies have demonstrated
that it is possible to significantly improve the structural
and functional properties of the peritoneum by
substituting one exchange of conventional PD solution
with either amino acid-based or icodextrin-based PD
solution (27). Recently, a more biocompatible glucose-
based PD solution has been formulated that makes use
of a two-chamber system, allowing the buffering system
to be more physiological, and glucose to be heat-sterilized
separately from other PD components, and thereby
reducing the generation of GDPs.
Therapeutic use of TGF-β1 antagonist
The fibrogenetic properties of TGF-β1 in peritoneal
fibrosis have been well documented (16,18,21-25).
Improved strategies to limit the over-expression of TGF-
β1 in the peritoneum during PD are thus critical in order
to preserve the integrity of the peritoneal membrane. In
and auto-induction of itself which significantly amplifies
its biological actions (9). In this context, studies by
independent researchers have shown that local
production of TGF-β1 within the peritoneum is increased
in patients maintained on PD, especially during episodes
of peritonitis as evident by elevated titers of TGF-β1 in
spent dialysates obtained from infected patients (16,19).
Furthermore, in vitro studies have demonstrated
convincingly that exogenous TGF-β1, or elevated
glucose-induced TGF-β1 significantly increased collagen
and fibronectin transcription and translation in human
peritoneal mesothelial cells (HPMC) (20-25). Ha et al
(22) observed that TGF-β1 exerts its fibrotic actions
through the activation of the diacylglycerol-protein
kinase C signal transduction pathway, a fibrogenic
mechanism analogous to that observed in diabetes
mellitus (26). Thus, to preserve the structural integrity
of the peritoneal membrane and its dialytic property, it
is imperative to design strategies to prevent glucose-
mediated TGF-β1-induction of peritoneal fibrosis.
PREVENTING PERITONEAL
FIBROSIS
The use of alternative osmotic agents in
peritoneal dialysis solutions
Glucose has been used effectively as the osmotic agent
in conventional PD solutions for more than 12 years. In
order to provide the osmotic drive, glucose con-
centrations must exceed 15 to 40 times that of
physiological concentrations (27). Even after
intraperitoneal equilibration, glucose concentration in the
peritoneal cavity can vary between six to 16 times that
of physiological levels (28), resulting in severe carbonyl
stress and promoting the formation of AGEs. Animal
biocompatibility studies undertaken by Gotloib et al (29)
have demonstrated convincingly that chronic glucose
exposure can alter mesothelial cell structure and function,
while in vitro studies in which cultured HPMC were
exposed to either elevated glucose concentrations or
GDPs significantly reduced cellular proliferation and
viability, whilst increasing matrix protein gene
expression and secretion (7,8,22). The majority of
biocompatibility studies have been performed using in
vitro mesothelial cultures. Although this approach of
study has provided important information on the
modulatory role of PD solutions on peritoneal cell
viability, function and matrix synthesis, it does not,
however, reflect the true clinical scenario. Specifically,
in vitro studies do not provide data on long-term changes
to the peritoneal structure nor on peritoneal transport
characteristics. This can only be achieved with either
longitudinal clinical studies or relevant in vivo animal
models of PD. Of the latter model, it is essential to choose
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an animal model of diabetic nephropathy, intraperitoneal
administration of anti-TGF-β1 over an 8-week period
resulted in significant improvement in renal function and
structure despite persistent hyperglycemia (34). Given
that peritoneal fibrosis and diabetic nephropathy are both
initiated by elevated glucose concentrations, it is perhaps
possible to extrapolate the diabetic experiments to animal
models of PD in the hope of obtaining similarly beneficial
results with neutralizing antibodies to TGF-β1. Other
possible approaches to antagonize aberrant synthesis of
TGF-β1 include the development of molecules that can
bind circulating or active TGF-β1 such as the soluble
receptor latency associated protein (35), or by targeting
the induction of TGF-β1 transcription. Thrombospondin-
1 is known to activate TGF-β1 in human mesangial cells
exposed to elevated glucose concentrations (36). The
employment of antagonists to thrombospondin-1 may
therefore also prove useful in ameliorating glucose-
initiated fibrosis.
One main concern of targeting TGF-β1 is that in addition
to its pro-fibrotic nature, TGF-β1 plays a pivotal role in
numerous physiological functions that include wound
healing and tissue injury, immune regulation and cancer
surveillance (37). In some tissues, for example in the
kidney, it has also been proposed that TGF-β1 plays an
essential role in the glomerular defense system that limits
inflammatory injury (38). In this respect, targeting TGF-
β1 needs to be meticulously designed to be both tissue-
and cell-specific, and the duration of anti-TGF-β1
therapy must be carefully selected to maximally reduce
peritoneal fibrosis, without compromising the
physiological response of peritoneal remodeling.
The use of glycosaminoglycans and
proteoglycans in the prevention of
peritoneal fibrosis
Proteoglycans are macromolecules ubiquitous in all
mammalian cells. They consist of a protein core and one
or more glycosaminoglycan chains. Glycosaminoglycans
are linear carbohydrate molecules composed of repeating
disaccharide units containing a hexuronic acid and a
hexosamine. Depending on the composition of their
disaccharides, five classes of glycosaminoglycan chains
have been categorized, namely chondroitin sulphate,
dermatan sulphate, heparan sulphate, keratan sulphate,
and hyaluronan (39). By virtue of their sulfate and
carboxyl groups, glycosaminoglycan chains are endowed
with a high net negative charge that are critical
determinants in their functional properties. These
macromolecules play a pivotal role in the selective
permeability of basement membranes, cell adhesion,
proliferation, migration, proteolysis, and sequestration
of growth factors (40,41).
Decorin is a small leucine-rich dermatan sulphate
proteoglycan that is found in the interstitial ECM of the
majority of tissues. It "decorates" connective tissue
matrices, participates in intercellular signaling, and helps
to maintain the structural integrity of tissues (9). It
comprises a 43-45kDa core protein that has been
demonstrated to bind to TGF-β1, and in doing so, block
its biological actions, thus ameliorating TGF-β1-induced
matrix synthesis (42). We have previously demonstrated
that the predominant proteoglycan synthesized and
secreted by cultured HPMC is decorin (43). How its
synthesis is modulated during PD remains to be fully
elucidated. Independent researchers have investigated the
potential role of decorin as a therapeutic agent in
attenuating fibrosis. Synthesis of recombinant decorin
is expensive and complex however, and would thus limit
the availability of decorin as an anti-fibrotic agent. Gene
therapy is a novel and alternative approach that can
deliver the complementary DNA (cDNA) of decorin into
the host's tissue to the site of injury. Gene therapy does
not allow the host cells to incorporate the cDNA protein
into their genome, but rather, the host cells utilize the
cDNA to synthesize the protein that is subsequently
secreted into the bloodstream, and can be delivered to
the vascular beds of tissues and organs. Expression of
the protein occurs transiently for up to 14 days, after
which the cDNA progressively degrades. Decorin has
been shown to be effective in abrogating renal and lung
fibrosis. Thus it is possible that decorin can be used as
an anti-fibrotic agent in the peritoneum during PD (9). A
recent study by Margetts et al (44) demonstrated that by
introducing adenovirus-mediated gene transfer of decorin
into a rat model of PD, hydroxyproline concentration (a
marker for collagen synthesis) within the mesenteric
tissue was significantly reduced. Clinical application of
gene therapy for PD have focussed on the peritoneal
mesothelial cells to be the primary target of gene transfer
to the peritoneal cavity since by virtue of their location
on both the visceral and parietal surfaces, they compose
a large population of target cells that actively participate
in inflammatory responses, tissue injury, and wound
healing, but further research is required before clinical
trials are possible (45).
Numerous studies have demonstrated the importance of
other glycosaminoglycans in the preservation of the
peritoneal structure and their role in tissue remodeling.
In this respect, animal studies have shown that heparin,
or Sulodexide, a heparinoid mixture consisting of heparin
or dermatan sulphate could maintain the structural and
functional integrity of the peritoneum by promoting
tissue remodeling, and reducing TGF-β1 synthesis,






Pharmacological interventional has been used with
success in the amelioration of cystic fibrosis, liver
fibrosis, and vascular sclerosis. Recent studies have
demonstrated that these drugs can also be extrapolated
to the peritoneal scenario in abrogating mesothelial cell
and peritoneal fibroblast induction of matrix synthesis.
Pentoxifylline (PTX; 3,7 dihydrox-3,7-dimethyl-1-(5-
oxohexyl)-1H-purine-2,6-dione) was init ially
characterized as a hemorheologic agent for the treatment
of vascular disease, increasing erythrocyte flexibility,
while reducing blood viscosity (48). The therapeutic
effects of PTX are not restricted to erythrocytes. Rather,
studies have demonstrated that PTX can alter the
biochemical and physical properties of platelets,
mononuclear leukocytes, macrophages, endothelial cells,
and fibroblasts (49-51). Pentoxifylline, by its ability to
inhibit intracellular cyclic AMP (cAMD) phospho-
diesterase, increases intracellular cAMP concentration
(52). The potential role of PTX as an anti-fibrotic agent
was first exemplified in human skin fibroblasts. In these
in vitro studies, Berman and Duncan (51) observed that
PTX could prevent fibroblast proliferation and induction
of matrix synthesis by modulating growth factor
synthesis. Recently, Fang et al (23) showed that PTX at
non-cytotoxic levels could inhibit serum induced cellular
proliferation and collagen type I synthesis in HPMC
through the increased synthesis of cAMP. Since PTX is
routinely used clinically in the treatment of peripheral
vascular disease, Fang and coworkers hypothesized that
it may be used as a therapeutic strategy in the prevention
of peritoneal fibrosis.
Dipyridamole has also been demonstrated to possess anti-
fibrogenic properties in a manner similar to PTX. Studies
by Hung et al (24) showed that incubation of HPMC
with dipyridamole prevented PDGF stimulated cellular
proliferation, increased cAMP levels, and abrogated the
activation of TGF-β1 signaling pathways, in particular
the extracellular signaling regulated protein kinase
pathway, and prevented the induction of collagen type I
transcription in HPMC.
We have recently highlighted the potential role of emodin
(3-methyl-1,6,8-trihydroxanthraquinoine) as an anti-
fibrotic agent (25,53). Emodin has been demonstrated
to inhibit protein kinase casein kinase II by competing
with its natural cosubstrate ATP, and in doing so,
modulates a variety of cellular functions such as
transcription, translation, signal transduction, and cell
cycle regulation (54). We have shown that emodin can
abrogate in vitro FCS-induced HPMC proliferation,
preserve elevated glucose mediated morphologic changes
in HPMC, and ameliorate high glucose-induction of
TGF-β1 and fibronectin synthesis by its ability to
abrogate elevated-glucose induced PKC-α activation and
inhibit phosphorylation of cAMP response element
binding protein (53).
Corticosteroid therapy has been used for over forty years
in the treatment of idiopathic pulmonary fibrosis in an
attempt to alleviate the inflammatory response commonly
associated with tissue fibrosis (55). The effect of
corticosteroids on peritoneal fibrosis remains undefined.
In this respect, in vitro studies have been undertaken by
Ogata et al (56) to investigate the modulating effect of
prednisolone on elevated glucose stimulated cultured
HPMC. These workers demonstrated that prednisolone
was able to reduce gene expression and secretion of high
ambient glucose-induced bFGF in HPMC. Furthermore,
studies by these researchers showed that when peritoneal
fibroblasts were incubated with mesothelial supernatant
obtained during drug treatment, fibroblast proliferation
and induction of fibronectin synthesis were abrogated
when compared to mesothelial supernatant obtained in
the absence of prednisolone. Although this in vitro study
shows the effective use of corticosteroids in the treatment
of experimental peritoneal fibrosis, should one extend
the studies to clinical trials, extreme care must be taken
since retrospective studies of IPF have shown
corticosteroid intervention to be associated with a myriad
of adverse effects that are associated with both the
duration and dose of treatment (57,58).
CONCLUSION
There is now compelling evidence to demonstrate that
chronic exposure of the peritoneum to conventional PD
solutions result in detrimental changes in both the
structural and functional integrity of the peritoneum,
compromising the dialytic efficacy of the peritoneal
membrane. Further knowledge of the mechanisms
underlying the pathogenesis of peritoneal fibrosis will
allow us to explore the application of novel strategies in
alleviating structural and functional alterations of the
peritoneum such that one can improve patient survival
on this treatment modality.
Acknowledgments
Work undertaken by the authors was supported by the
Hong Kong Research Grants Council Earmarked
Research Grant (7274/98M) and also by The School of
Traditional Chinese Medicine Research Fund, the
University of Hong Kong (10212.00000001).
REFERENCES
1. Mutsaers SE. Mesothelial cells: their structure, function and role in
serosal repair. Respirology 2002;7:171-91.
13
Hong Kong J Nephrol 2003;5(1):8-14. S YUNG, TM CHAN
2. Topley N, Williams JD. The role of the peritoneal membrane in the
control of inflammation in the peritoneal cavity. Kidney Int 1994;46
(Suppl):S71-8.
3. de Vriese AS, Tilton RG, Stephan CC, Lameire NH. Vascular
endothelial growth factor is essential for hyperglycemia-induced
structural and functional alterations of the peritoneal membrane. J
Am Soc Nephrol 2001;12:1734-41.
4. Zweers MM, de Waart DR, Smit W, Struijk DG, Krediet RT. Growth
factors VEGF and TGF-beta1 in peritoneal dialysis. J Lab Clin Med
1999;134:124-32.
5. Dobbie JW. Ultrastructural and pathology of the peritoneum in
peritoneal dialysis. In: Gokal R, Nolph KD, eds. The Textbook of
Peritoneal Dialysis. The Netherlands: Kluwer Academic Publishers;
1994:17-44.
6. Henderson IS, Couper IA, Lumsden A. Potentially irritant glucose
metabolites in unused CAPD fluids. In: Maher JF, Winchester JF,
eds. Frontiers in Peritoneal Dialysis. New York: Field, Rich and
Assoc; 1986:261-4.
7. Witowski J, Korybalska K, Wisniewska J, Breborowicz A, Gahl GM,
Frei U, Passlick-Deetjen J, Jorres A. Effect of glucose degradation
products on human peritoneal mesothelial cell function. J Am Soc
Nephrol 2000;11:729-39.
8. Witowski J, Wisniewska J, Korybalska K, Bender TO, Breborowicz
A, Gahl GM, Frei U, Passlick-Deetjen J, Jorres A. Prolonged
exposure to glucose degradation products impairs viability and
function of human peritoneal mesothelial cells. J Am Soc Nephrol
2001;12:2434-41.
9. Border WA, Noble NA. TGF-β in kidney fibrosis. Kidney Int 1997;
51:1388-96.
10.Williams JD, Craig KJ, Topley N, von Ruhland C, Fallon M, Newman
GR, Mackenzie RK, Williams GT. Morphologic changes in the
peritoneal membrane of patients with renal disease. J Am Soc
Nephrol 2002;13:470-9.
11. Krediet RT, Lindholm B, Rippe B. Pathophysiology of peritoneal
membrane failure. Perit Dial Int 2000;20(Suppl): S22-42.
12.Honda K, Nitta K, Horita S, Yumura W, Nihei H, Nagai R, Ikeda K,
Horiuchi S. Accumulation of advanced glycation end products in
the peritoneal vasculature of continuous ambulatory peritoneal
dialysis patients with low ultra-filtration. Nephrol Dial Transplant
1999;14:1541-9.
13.Honda K, Nitta K, Horita S, Yumura W, Nihei H. Morphological
changes in the peritoneal vasculature of patients on CAPD with
ultrafiltration failure. Nephron 1996;72:171-6.
14.Gotloib L, Bar-Sella P, Shostak A. Reduplicated basal lamina of
small venules and mesothelium of human parietal peritoneum:
ultrastructural changes of reduplicated peritoneal basement
membrane. Perit Dial Bull 1985;5:212-5.
15.Mateijsen MA, van der Wal AC, Hendriks PM, Zweers MM, Mulder
J, Struijk DG, Krediet RT. Vascular and interstitial changes in the
peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial
Int. 1999;19:517-25.
16.Lin CY, Chen WP, Yang LY, Chen A, Huang TP. Persistent
transforming growth factor-beta 1 expression may predict peritoneal
fibrosis in CAPD patients with frequent peritonitis occurrence. Am
J Nephrol 1998;18:513-9.
17.Cronauer MV, Stadlmann S, Klocker H, Abendstein B, Eder IE,
Rogatsch H, Zeimet AG, Marth C, Offner FA. Basic fibroblast growth
factor synthesis by human peritoneal mesothelial cells: induction
by interleukin-1. Am J Pathol 1999;155:1977-84.
18.Hung KY, Chen CT, Yen CJ, Lee PH, Tsai TJ, Hsieh BS.
Dipyridamole inhibits PDGF-stimulated human peritoneal
mesothelial cell proliferation. Kidney Int 2001;60:872-81.
19.Lai KN, Lai KB, Lam CW, Chan TM, Li FK, Leung JC. Changes of
cytokine profiles during peritonitis in patients on continuous
ambulatory peritoneal dialysis. Am J Kid Dis 2000;35:644-52.
20.Ha H, Lee HB. Effect of high glucose on peritoneal mesothelial cell
biology. Perit Dial Int 2000;20(Suppl):S15-8.
21.Medcalf JF, Walls J, Pawluczyk IZA, Harris KPG. Effects of glucose
dialysate on extracellular matrix production by human peritoneal
mesothelial cells (HPMC): the role of TGF-β. Nephrol Dial Transplant
2001;16:1885-92.
22.Ha H, Yu MR, Lee HB. High glucose-induced PKC activation
mediates TGF-β1 and fibronectin synthesis by peritoneal
mesothelial cells. Kidney Int 2001;59:463-70.
23.Fang CC, Yenh CJ, Chen YM, Shyu RS, Tsai TJ, Lee PH, et al.
Pentoxifelline inhibit human peritoneal mesothelial cell growth and
collagen synthesis: effects on TGF-β. Kidney Int 2000;57:2626-33.
24.Hung KY, Chen CT, Huang JW, Lee PH, Tsai TJ, Hsieh BS.
Dipyridamole inhibits TGF-β-induced collagen gene expression in
human peritoneal mesothelial cells. Kidney Int 2001;60:1249-57.
25.Yung S, Liu ZH, Lai KN, Li LS, Chan TM. Emodin ameliorates
glucose-induced morphologic abnormalities and synthesis of
transforming growth factor beta1 and fibronectin by human
peritoneal mesothelial cells. Perit Dial Int 2001;21(Suppl):S41-7.
26.Way KJ, Katai N, King GL. Protein kinase C and the development
of diabetic vascular complications. Diabet Med 2001;18:945-59.
27.Holmes CJ, Shockley TR. Strategies to reduce glucose exposure
in peritoneal dialysis patients. Perit Dial Int 2000; 20(Suppl):S37-
41.
28.Coles GA, Topley N. Long-term peritoneal membrane changes. Adv
Ren Replace Ther 2002;7:289-301.
29.Gotloib L, Shostak A, Wajsbrot V, Kuschnier R. Biocompatibility of
dialysis solutions evaluated by histochemical techniques applied
to mesothelial cell imprints. Perit Dial Int 1993;13(Suppl):S113-5.
30.Di Paolo N, Sacchi G. Peritoneal vascular changes in continuous
ambulatory peritoneal dialysis (CAPD): an in vivo model for the
study of diabetic microangiopathy. Perit Dial Int 1989;9:41-5.
31.Davies SJ, Phillips L, Naish PF, Russel GI. Peritoneal glucose
exposure and changes in membrane solute transport with time on
peritoneal dialysis. J Am Soc Nephrol 2001;12:1046-51.
32. Jones M, Hagen T, Boyle CA, Vonesh E, Hamburger R, Charttan
C, Sandroni S, Bernard D, Piraino B, Schreiber M, Gehr T, Fein P,
Friedlander M, Burkart J, Ross D, Zimmerman S, Swartz R, Knight
T, Kraus A Jr, McDonald L, Hartnett M, Weaver M, Martis L, Moran
J. Treatment of malnutrition with 1.1% amino acid peritoneal dialysis
solution: results of a multicenter outpatient study. Am J Kid Dis
1998;32:761-9.
33.Krediet RT, Brown CB, Imholz ALT, Koomen GCM. Protein
clearance and icodextrin. Perit Dial Int 1994;14(Suppl):S39-44.
34.Ziyadeh FN, Hoffman BB, Han DC, Iglesias-de la Cruz MC, Hong
SW, Isono M, Chen S, McGowan TA, Sharma K. long-term
prevention of renal insufficiency, excess matrix gene expression,
and glomerular mesangial matrix expansion by treatment with
monoclonal antitransforming growth factor-β antibody in db/db
diabetic mice. Proc Natl Acad Sci USA 2000;97:8015-20.
35.Bottinger E, Factor V, Tsang M, Weatherbee J, Kopp J, Qian SW,
Wakefield LM, Roberts AB, Thorgeirsson SS, Sporn MB. The
recombinant proregion of transforming growth factor beta1 (latency-
associated peptide) inhibits active transforming growth factor beta1
in transgenic mice. Proc Natl Acad Sci USA 1996;93:5877-82.
36.Ribeiro S, Poczatek M, Schultz-Cherry S, Villain M, Murphy-Ullrich
J. The activation sequence of thrombospondin-1 interacts with the
14
Preventing peritoneal fibrosis
latency-associated peptide to regulate activation of the latent
transforming growth factor -β. J Biol Chem 1999;274:13586-93.
37. Branton MH, Kopp JB. TGF-β and fibrosis. Microbes Infect 1999;1:
1349-65.
38.Kitamura M, Fine LG. The concept of glomerular self-defense.
Kidney Int 1999;55:1639-71.
39.Hardingham TE, Fosang AJ. Proteoglycans: many forms and many
functions. FASEB J 1992;6:861-70.
40.Esko JD. Genetic analysis of proteoglycan structure, function and
metabolism. Curr Opin Cell Biol 1991;3:805-16.
41.Groffen AJA, Veerkamp JH, Monnens LAH, van den Heuvel LPWJ.
Recent insights into the structure and functions of heparan sulfate
proteoglycans in the human glomerular basement membrane.
Nephrol Dial Transplant 1999;14:2119-29.
42.Border WA, Noble NA, Yamamoto T, Tomooka S, Kagami S.
Antagonists of transforming growth factor-β. A novel approach to
treatment of glomerulosclerosis. Kidney Int 1992;41:566-70.
43.Yung S, Thomas GJ, Stylianou E, Williams JD, Coles GA, Davies
M. Source of peritoneal proteoglycans. Human peritoneal
mesothelial cells synthesize and secrete mainly small dermatan
sulfate proteoglycans. Am J Pathol 1995;146:520-9.
44.Margetts, PJ, Gyorffy S, Kolb M, Yu L, Hoff CM, Holmes CJ, Gauldie
J. Antiangiogenic and antifibrotic gene therapy in a chronic infusion
model of peritoneal dialysis in rats. J Am Soc Nephrol 2002;13:
721-8.
45.Hoff CM, Shockley TR. Peritoneal dialysis in the 21st century: the
potential of gene therapy. J Am Soc Nephrol 2002;13(Suppl):S117-
24.
46.Fracasso A, Baggio B, Ossi E, Del Prete D, Bonfante L, Bazzato G,
Gambaro G. Glycosaminoglycans prevent the functional and
morphological peritoneal derangement in an experimental model
of peritoneal fibrosis. Am J Kid Dis 1999;33:105-10.
47.Gambaro G, Baggio B. Glycosaminoglycans: a new paradigm in
the prevention of proteinuria and progression of glomerular disease.
Nephrol Dial Transplant 1996;11:762-4.
48.Muller R. Hemorrheology and peripheral vascular diseases: a new
therapeutic approach. J Med 1981;12:209-35.
49.Gastpar H, Ambrus JL, Ambrus CM, Spavento P, Wever FJ, Thurber
LE. Study of platelet aggregation in vivo [I]: effect of pentoxifylline.
J Med 1997;8:191-7.
50.Weithmann KU. The influence of pentoxifylline on interaction
between blood vessel wall and platelets. IRCS Med Sci 1980;8:
293-4.
51.Berman B, Duncan MR. Pentoxifylline inhibits normal human dermal
fibroblast in vitro proliferation, collagen, glycosaminoglycan, and
fibronectin production, and increases collagenase activity. J Invest
Dermatol 1989;82:605-10.
52.Windmeier C, Gressner AM. Pharmacological aspects of
pentoxifylline with emphasis on its inhibitory actions on hepatic
fibrogenesis. Gen Pharmacol 1997;29:181-96.
53.Yung S, Lui ZH, Li LS, Lai KN, Chan TM. Emodin ameliorate
excessive fibronectin synthesis by human peritoneal mesothelial
cells (HPMC). J AM Soc Nephrol 2001;12:722.
54.Battistutta R, Sarno S, Moliner ED, Papinutto E, Zanotti G, Pinna
LA. The replacement of ATP by the competitive inhibitor emodin
induces conformational modifications in the catalytic site of protein
kinase CK2. J Biol Chem 2000;38:29618-22.
55.Lynch JP III, White E, Flaherty K. Corticosteroids in idiopathic
pulmonary fibrosis. Curr Opin Pulm Med 2001;7:298-308.
56.Ogata S, Yorioka N, Kohno N. Glucose and prednisolone alter basic
fibroblast growth factor expression in peritoneal mesothelial cells
and fibroblasts. J Am Soc Nephrol 2001;12:2787-96.
57.Walsh LJ, Wong CA, Oborne J, Cooper S, Lewis SA, Pringle M,
Hubbard R, Tattersfield AE. Adverse effects of oral corticosteroids
in elation to dose in patients with lung disease. Thorax 2001;56:
279-84.
58.Seale JP, Compton MR. Side-effects of corticosteroid agents. Med
J Aust 1986;144:139-42.
